{"title":"共同补充益生菌和维生素 D 对偏头痛成年患者的临床症状、心理健康和炎症的影响:一项随机、三重盲法、安慰剂对照试验。","authors":"Shahnaz Amani Tirani, Fariborz Khorvash, Parvane Saneei, Zahra Moradmand, Gholamreza Askari","doi":"10.1186/s12916-024-03684-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Migraine headache is a major public health problem. Routine medications for migraine treatment are not useful in treating all patients and may have some side effects. The present study aimed to investigate the effect of vitamin D and probiotic co-supplementation on clinical characteristics of migraine, daily functioning, mental health outcomes, and serum levels of high-sensitivity C-reactive protein (hs-CRP).</p><p><strong>Methods: </strong>In this randomized, triple-blinded, placebo-controlled trial, patients aged 18 to 55 years diagnosed with migraine based on the International Classification of Headache Disorders-3 (ICHD-3) were randomized to either vitamin D (50,000 IU every 2 weeks) plus probiotic (4.5 × 10<sup>11</sup> CFU per day) or placebo for 12 weeks. The Headache Impact Test (HIT-6) and Depression, Anxiety, and Stress Scale (DASS) questionnaires were administered to patients at baseline and after 12 weeks. In addition, the frequency, duration, and severity of migraine headaches per month were assessed using a self-administered 30-day headache diary at baseline and the end of the intervention. Anthropometric indices, blood pressure, and serum levels of 25-hydroxy vitamin D and hs-CRP were also examined at first and the end of the study.</p><p><strong>Results: </strong>Seventy-two migraine patients with a mean age of 37.46 <math><mo>±</mo></math> 8.32 years were included in this trial. Probiotic and vitamin D co-supplementation compared to placebo resulted in a significant increase in serum levels of vitamin D (+ 12.86 <math><mo>±</mo></math> 1.64 vs. + 1.12 <math><mo>±</mo></math> 0.80 ng/mL, P < 0.001). The between-group analysis in the adjusted model showed a significantly greater reduction in migraine headache frequency (- 3.17 <math><mo>±</mo></math> 0.84 vs. - 1.25 <math><mo>±</mo></math> 0.34; P = 0.031) and severity (- 1.55 <math><mo>±</mo></math> 0.35 vs. + 0.67 <math><mo>±</mo></math> 0.29; P = 0.017) in the probiotic and vitamin D group than the placebo group. No significant difference was found between the two arms of the intervention regarding the change in headache duration, hs-CRP, scores of DASS, and HIT-6 questionnaires (P > 0.05).</p><p><strong>Conclusions: </strong>This trial showed that probiotic and vitamin D co-supplementation for 12 weeks has beneficial effects on migraine headache characteristics. Further research is needed to confirm this finding.</p>","PeriodicalId":9188,"journal":{"name":"BMC Medicine","volume":"22 1","pages":"457"},"PeriodicalIF":7.0000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470646/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effects of probiotic and vitamin D co-supplementation on clinical symptoms, mental health, and inflammation in adult patients with migraine headache: a randomized, triple-blinded, placebo-controlled trial.\",\"authors\":\"Shahnaz Amani Tirani, Fariborz Khorvash, Parvane Saneei, Zahra Moradmand, Gholamreza Askari\",\"doi\":\"10.1186/s12916-024-03684-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Migraine headache is a major public health problem. Routine medications for migraine treatment are not useful in treating all patients and may have some side effects. The present study aimed to investigate the effect of vitamin D and probiotic co-supplementation on clinical characteristics of migraine, daily functioning, mental health outcomes, and serum levels of high-sensitivity C-reactive protein (hs-CRP).</p><p><strong>Methods: </strong>In this randomized, triple-blinded, placebo-controlled trial, patients aged 18 to 55 years diagnosed with migraine based on the International Classification of Headache Disorders-3 (ICHD-3) were randomized to either vitamin D (50,000 IU every 2 weeks) plus probiotic (4.5 × 10<sup>11</sup> CFU per day) or placebo for 12 weeks. The Headache Impact Test (HIT-6) and Depression, Anxiety, and Stress Scale (DASS) questionnaires were administered to patients at baseline and after 12 weeks. In addition, the frequency, duration, and severity of migraine headaches per month were assessed using a self-administered 30-day headache diary at baseline and the end of the intervention. Anthropometric indices, blood pressure, and serum levels of 25-hydroxy vitamin D and hs-CRP were also examined at first and the end of the study.</p><p><strong>Results: </strong>Seventy-two migraine patients with a mean age of 37.46 <math><mo>±</mo></math> 8.32 years were included in this trial. Probiotic and vitamin D co-supplementation compared to placebo resulted in a significant increase in serum levels of vitamin D (+ 12.86 <math><mo>±</mo></math> 1.64 vs. + 1.12 <math><mo>±</mo></math> 0.80 ng/mL, P < 0.001). The between-group analysis in the adjusted model showed a significantly greater reduction in migraine headache frequency (- 3.17 <math><mo>±</mo></math> 0.84 vs. - 1.25 <math><mo>±</mo></math> 0.34; P = 0.031) and severity (- 1.55 <math><mo>±</mo></math> 0.35 vs. + 0.67 <math><mo>±</mo></math> 0.29; P = 0.017) in the probiotic and vitamin D group than the placebo group. No significant difference was found between the two arms of the intervention regarding the change in headache duration, hs-CRP, scores of DASS, and HIT-6 questionnaires (P > 0.05).</p><p><strong>Conclusions: </strong>This trial showed that probiotic and vitamin D co-supplementation for 12 weeks has beneficial effects on migraine headache characteristics. Further research is needed to confirm this finding.</p>\",\"PeriodicalId\":9188,\"journal\":{\"name\":\"BMC Medicine\",\"volume\":\"22 1\",\"pages\":\"457\"},\"PeriodicalIF\":7.0000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11470646/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12916-024-03684-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12916-024-03684-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:偏头痛是一个重大的公共健康问题。治疗偏头痛的常规药物并非对所有患者都有用,而且可能会产生一些副作用。本研究旨在探讨维生素 D 和益生菌共同补充对偏头痛临床特征、日常功能、心理健康结果以及血清高敏 C 反应蛋白(hs-CRP)水平的影响:在这项随机、三盲、安慰剂对照试验中,根据《国际头痛疾病分类-3》(ICHD-3)被诊断为偏头痛的 18 至 55 岁患者被随机分配到维生素 D(每两周 50,000 IU)加益生菌(每天 4.5 × 1011 CFU)或安慰剂的治疗方案中,为期 12 周。在基线和 12 周后,对患者进行了头痛影响测试 (HIT-6) 和抑郁、焦虑和压力量表 (DASS) 问卷调查。此外,在基线和干预结束时,还使用自我管理的 30 天头痛日记对偏头痛的频率、持续时间和每月头痛的严重程度进行了评估。在研究开始和结束时,还对人体测量指数、血压以及血清中 25- 羟基维生素 D 和 hs-CRP 的水平进行了检测:72名偏头痛患者参加了此次试验,他们的平均年龄为(37.46 ± 8.32)岁。与安慰剂相比,益生菌和维生素D联合补充组的血清维生素D水平(+ 12.86 ± 1.64 vs. + 1.12 ± 0.80 ng/mL,P ± 0.84 vs. - 1.25 ± 0.34;P = 0.031)和严重程度(- 1.55 ± 0.35 vs. + 0.67 ± 0.29;P = 0.017)均显著高于安慰剂组。在头痛持续时间、hs-CRP、DASS评分和HIT-6问卷的变化方面,两组干预措施之间没有发现明显差异(P > 0.05):这项试验表明,益生菌和维生素 D 联合补充疗法持续 12 周对偏头痛的特征具有有益影响。需要进一步的研究来证实这一发现。
Effects of probiotic and vitamin D co-supplementation on clinical symptoms, mental health, and inflammation in adult patients with migraine headache: a randomized, triple-blinded, placebo-controlled trial.
Background: Migraine headache is a major public health problem. Routine medications for migraine treatment are not useful in treating all patients and may have some side effects. The present study aimed to investigate the effect of vitamin D and probiotic co-supplementation on clinical characteristics of migraine, daily functioning, mental health outcomes, and serum levels of high-sensitivity C-reactive protein (hs-CRP).
Methods: In this randomized, triple-blinded, placebo-controlled trial, patients aged 18 to 55 years diagnosed with migraine based on the International Classification of Headache Disorders-3 (ICHD-3) were randomized to either vitamin D (50,000 IU every 2 weeks) plus probiotic (4.5 × 1011 CFU per day) or placebo for 12 weeks. The Headache Impact Test (HIT-6) and Depression, Anxiety, and Stress Scale (DASS) questionnaires were administered to patients at baseline and after 12 weeks. In addition, the frequency, duration, and severity of migraine headaches per month were assessed using a self-administered 30-day headache diary at baseline and the end of the intervention. Anthropometric indices, blood pressure, and serum levels of 25-hydroxy vitamin D and hs-CRP were also examined at first and the end of the study.
Results: Seventy-two migraine patients with a mean age of 37.46 8.32 years were included in this trial. Probiotic and vitamin D co-supplementation compared to placebo resulted in a significant increase in serum levels of vitamin D (+ 12.86 1.64 vs. + 1.12 0.80 ng/mL, P < 0.001). The between-group analysis in the adjusted model showed a significantly greater reduction in migraine headache frequency (- 3.17 0.84 vs. - 1.25 0.34; P = 0.031) and severity (- 1.55 0.35 vs. + 0.67 0.29; P = 0.017) in the probiotic and vitamin D group than the placebo group. No significant difference was found between the two arms of the intervention regarding the change in headache duration, hs-CRP, scores of DASS, and HIT-6 questionnaires (P > 0.05).
Conclusions: This trial showed that probiotic and vitamin D co-supplementation for 12 weeks has beneficial effects on migraine headache characteristics. Further research is needed to confirm this finding.
期刊介绍:
BMC Medicine is an open access, transparent peer-reviewed general medical journal. It is the flagship journal of the BMC series and publishes outstanding and influential research in various areas including clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities. In addition to research articles, the journal also publishes stimulating debates, reviews, unique forum articles, and concise tutorials. All articles published in BMC Medicine are included in various databases such as Biological Abstracts, BIOSIS, CAS, Citebase, Current contents, DOAJ, Embase, MEDLINE, PubMed, Science Citation Index Expanded, OAIster, SCImago, Scopus, SOCOLAR, and Zetoc.